3[2]Hill BT,Basiley BD, white JC,et al. Characteristic of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts,one with impaired transport of methotrexate [J] . Cancer Res,1979 ,39:2440.
4周际昌.实用肿瘤内科学[M].第2版.北京:人民卫生出版社,2002:344.
5赫捷,赵平,陈万青.2012年中国肿瘤登记年报[M].北京:北京军事医学科学出版社,2013.
6Morton LM, Wang SS, Devesa SS, et al.Lymphoma incidence patterns by WHO subtype in the United States, 1992 -2001 [J]. Blood,2006,107 ( 1 ) :265 -276.
7Saidel H, Nygaard R, Moe PJ, et al. On the prognostic value of systemic methotrexate clearance in childhood acute lymphoblastic leukaemia [J]. Leuk Res,1997,21(5):429-434.
8Aumente D, Buelga DS, Lukas JC, et al.Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastie leukaemia [J]. Chn Pharmacokinet, 2006,45(12):1227-1238.
9Kanbayashi Y1, Nomura K, Okamoto K,et al. Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis [J].Ann Hematol, 2010,89(10): 965-969.
10Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastie leukemia [J]. Leukemia,2006,20( 11 ): 1955-1962.
